Chronic Cough Market Scope And Analysis

Chronic Cough Market Report Scope

Chronic Cough Market News and Recent Developments

The chronic cough market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for chronic cough:

• Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, announced the initiation of its Phase 2b CORAL clinical trial evaluating three doses of Haduvio against placebo in approximately 160 IPF patients with chronic cough. (Source: The Trevi Therapeutics, Press Release, 2023)
• Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 (“Ifenprodil”) research program. (Source: Algernon Pharmaceuticals Inc., Press Release, 2024)

Chronic Cough Market Report Coverage and Deliverables

The “Chronic CoughMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles